Calls Purchased on Cell Therapeutics, Inc. (CTIC)
October 14, 2010 11:28 AM
Shares of Cell Therapeutics, Inc. (NASDAQ: CTIC) are higher on the session by 7.35%, currently trading at $0.4149. The stock has been moving largely lower for the past six months, though has recently begun to base sideways around the 200-day moving average.
Options traders are buying calls on the name today. A short while ago the November $1.00 call was purchased 1,000 times, on the offer, and the January 2012 $1.00 call was purchased 3,980 times, on the offer. Volume did not exceed open interest on either strike.
Overall call volume is now running at 4.76x the daily average, 100% on the offer.
Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer.
For more great research like this, as well as how to play it through options…please visit Benzinga’s Options & Volatility Edge and Benzinga’s Cash Generator.
